In vitro activity of BAY v 3522, a new cephalosporin for oral administration.
The activity of BAY v 3522 was tested against over 500 clinical bacterial isolates and compared with the activities of ampicillin, amoxicillin-clavulanate, cefaclor, cefixime, cefuroxime, cephalexin, and/or ciprofloxacin, erythromycin, and metronidazole. BAY v 3522 activity against staphylococci and streptococci equaled or exceeded those of the other agents. BAY v 3522 exhibited no significant advantage over cefaclor, cefuroxime, or cephalexin against gram-negative bacilli.
Hodges
T L
TL
Department of Medicine, New England Deaconess Hospital, Boston, Massachusetts.
Eliopoulos
G M
GM
Klimm
K
K
Moellering
R C
RC
D000284:Administration, Oral; D001419:Bacteria / Q000187:drug effects; D052160:Benzothiazoles; D002511:Cephalosporins / Q000008:administration & dosage / Q000494:pharmacology*; D008826:Microbial Sensitivity Tests; D013210:Staphylococcus / Q000187:drug effects; D013291:Streptococcus / Q000187:drug effects
D052160:Benzothiazoles; D002511:Cephalosporins; C064738:Bay v 3522